ARA-290 (Cibinetide / Helix B Surface Peptide)

Comprehensive Research Analysis - Tissue-Protective EPO-Derived Peptide

Classification: Non-Erythropoietic EPO-Derived Peptide, Innate Repair Receptor Agonist Alternative Names: Cibinetide, HBSP (Helix B Surface Peptide), pHBSP Amino Acid Sequence: QEQLERALNSS (11 amino acids) Chemical Formula: C₅₁H₅₄N₁₆O₂₁ Molecular Weight: 1,257.3 g/mol Research Status: Phase II/III Clinical Trials (Active Development) WADA Status: Not Listed on Prohibited List (as of 2025)

1. Executive Summary

ARA-290, also known as Cibinetide or Helix B Surface Peptide (HBSP), is a synthetic 11-amino acid peptide engineered from the helix-B domain of erythropoietin (EPO) [1]. Unlike full-length EPO, ARA-290 retains tissue-protective and anti-inflammatory properties without stimulating red blood cell production (erythropoiesis) [2], making it a breakthrough in regenerative medicine and chronic pain management.

The peptide's mechanism centers on activation of the Innate Repair Receptor (IRR), a heterodimeric complex formed by the erythropoietin receptor (EPOR) and beta common receptor (CD131) [3]. Through IRR signaling, ARA-290:

• Reduces neuropathic pain (40% reduction in sarcoidosis trials) [4]
• Regenerates small nerve fibers (increases corneal nerve density)
• Suppresses chronic inflammation (modulates microglia and macrophage activation)
• Protects vital organs (kidneys, heart, brain) from ischemic and oxidative injury [5]

Clinical Trial Evidence:

• Phase II Diabetic Neuropathy: Improved neuropathic symptoms and metabolic control in type 2 diabetes patients [1]
• Phase II Sarcoidosis Neuropathy: Significantly reduced pain scores and increased corneal nerve fiber density [6]
• Safety: Excellent tolerability across all trials; no serious adverse events [7]

Regulatory Status:

• FDA Fast Track Designation: Granted for sarcoidosis-associated small fiber neuropathy [8]
• Orphan Drug Designation: For neuropathic pain in sarcoidosis [9]
• Current Stage: Phase II/III clinical development; not yet FDA-approved

Unique Pharmacokinetics: Despite an ultra-short plasma half-life (~20 minutes), ARA-290 produces sustained biological effects lasting days to weeks [10]. This phenomenon, termed a "molecular switch," results from prolonged downstream signaling cascade activation even after the peptide is cleared.

Current Use: Available only through clinical trials and research channels. Not approved for clinical practice but shows exceptional promise for diabetic neuropathy, sarcoidosis, chronic pain, and neurodegenerative diseases.

Goal Relevance:

• Relief from chronic pain and discomfort associated with conditions like sarcoidosis and diabetic neuropathy
• Support for nerve regeneration and recovery, particularly for those experiencing neuropathic symptoms
• Reduction of inflammation and support for managing autoimmune conditions
• Protection and recovery of vital organs such as the heart, kidneys, and brain from injury or stress
• Improvement in quality of life for individuals with neurodegenerative diseases through protective and regenerative effects
• Assistance in managing and reducing symptoms of diabetic neuropathy for better metabolic control

2. Chemical Structure & Composition

Molecular Profile

Amino Acid Sequence: QEQLERALNSS

Position:  1   2   3   4   5   6   7   8   9  10  11
Residue:   Q   E   Q   L   E   R   A   L   N   S   S
           Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

Chemical Formula: C₅₁H₅₄N₁₆O₂₁ Molecular Weight: 1,257.3 g/mol [11] Isoelectric Point (pI): Approximately 4.5 (acidic peptide due to Glu residues)

Derivation from Erythropoietin

ARA-290 is derived from the helix-B domain of human erythropoietin (EPO), spanning residues that correspond to a specific surface region of EPO's tertiary structure [12].

EPO Structure Overview:

• Full-length EPO: 165 amino acids, ~30 kDa glycoprotein
• Four alpha-helices (A, B, C, D) form 3D structure
• Helix-B domain: Responsible for tissue protection, NOT erythropoiesis

Engineering Strategy:

1. Identify EPO regions responsible for tissue protection vs. RBC production
2. Isolate helix-B sequence (QEQLERALNSS) as minimal active fragment
3. Synthesize 11-amino acid linear peptide

Result: A peptide that mimics EPO's tissue-protective effects without cardiovascular risks associated with increased hematocrit (polycythemia, hypertension, thrombosis).

Chemical Properties

• Solubility: High aqueous solubility (>50 mg/mL); peptide is hydrophilic
• Stability: Stable in lyophilized form; prone to oxidation in solution (Cys-free; no disulfide concerns)
• pH Stability: Optimal at physiological pH (7.0–7.4)
• Charge: Net negative charge at pH 7.4 (two Glu residues, one Arg)

Post-Translational Modifications

ARA-290 is a synthetic linear peptide with no glycosylation or other PTMs (unlike full-length EPO, which is heavily glycosylated).

Advantages of Non-Glycosylation:

• Easier to synthesize (solid-phase peptide synthesis)
• Lower production cost than recombinant EPO
• Consistent batch-to-batch quality

3. Mechanism of Action

Innate Repair Receptor (IRR) Activation

ARA-290's biological effects are mediated entirely through the Innate Repair Receptor (IRR) [3], a heterodimeric receptor complex distinct from the classical EPO receptor responsible for erythropoiesis.

IRR Composition:

• EPOR (Erythropoietin Receptor): Subunit shared with classical EPO signaling
• CD131 (β Common Receptor): Also known as βc or CSF2RB; shared by IL-3, IL-5, GM-CSF receptors

Key Distinction:

• Classical EPO Receptor (Erythropoiesis): EPOR homodimer
• Innate Repair Receptor (Tissue Protection): EPOR + CD131 heterodimer

Binding Selectivity: ARA-290 binds selectively to the EPOR/CD131 heterodimer, NOT the EPOR homodimer [13]. This explains why the peptide lacks erythropoietic activity.

Signal Transduction Cascade

Upon ARA-290 binding to IRR:

1. Receptor Dimerization & Activation:

• EPOR and CD131 subunits heterodimerize
• JAK2 kinases (associated with cytoplasmic tails) cross-phosphorylate
• Receptor tyrosine phosphorylation creates docking sites

2. STAT3 Activation:

• Signal Transducer and Activator of Transcription 3 (STAT3) is the primary downstream effector [10]
• Phosphorylated STAT3 (pSTAT3) translocates to nucleus
• Activates gene transcription programs

3. PI3K/AKT Pathway:

• Parallel activation of phosphoinositide 3-kinase (PI3K)
• AKT phosphorylation promotes cell survival
• Inhibits apoptotic pathways (Bax, caspase-3)

4. NF-κB Modulation:

• Suppresses pro-inflammatory NF-κB signaling
• Reduces cytokine production (TNF-α, IL-1β, IL-6)

5. Anti-Apoptotic Proteins:

• Upregulates Bcl-2, Bcl-xL (survival factors)
• Downregulates Bax, caspase activation

Tissue-Specific Effects

Neuroprotection & Nerve Regeneration

ARA-290 demonstrated remarkable efficacy in regenerating small nerve fibers (C-fibers and Aδ-fibers responsible for pain and temperature sensation):

Mechanism:

• Suppresses spinal cord microglia activation (reduces neuroinflammation) [3]
• Promotes Schwann cell survival and myelination
• Increases nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) expression
• Restores mitochondrial function in damaged neurons

Clinical Evidence:

• Sarcoidosis trial: Increased corneal nerve fiber density by 14.5% after 4 weeks [6]
• Diabetic neuropathy: 40% reduction in neuropathic pain scores [1]

Anti-Inflammatory Effects

ARA-290 modulates immune cell function:

Macrophage/Microglia Modulation:

• Shifts macrophages from M1 (pro-inflammatory) to M2 (tissue-repair) phenotype [14]
• Reduces microglial activation in CNS (critical for neuropathic pain)
• Suppresses cytokine storm in inflammatory conditions

Systemic Inflammation:

• Reduces circulating inflammatory markers (CRP, TNF-α, IL-6) [10]
• Protects against LPS-induced septic shock in animal models

Organ Protection (Ischemia/Reperfusion Injury)

Kidney Protection:

• Reduces ischemia/reperfusion injury in renal transplant models [15]
• Protects tubular epithelial cells from oxidative stress
• Decreases acute kidney injury markers (creatinine, BUN)

Cardiac Protection:

• Reduces infarct size in myocardial ischemia models [16]
• Attenuates age-related cardiac decline
• Prolongs healthspan in preclinical models

Brain Protection:

• Reduces neuronal death in stroke models
• Improves cognitive function in neurodegenerative disease models [14]

Metabolic Effects

Glucose Homeostasis:

• Phase II trial showed improved HbA1c and fasting glucose in diabetic patients [1]
• Mechanism: Reduced insulin resistance via anti-inflammatory effects
• Enhanced pancreatic β-cell survival

Weight Management:

• Modest reductions in body weight observed in some trials
• May relate to improved metabolic efficiency and reduced inflammation

"Molecular Switch" Phenomenon

Paradox: ARA-290 has an ultra-short half-life (~20 minutes plasma, ~2 minutes tissue) [10], yet produces effects lasting days to weeks.

Explanation:

• Brief ARA-290 binding triggers sustained phosphorylation cascades
• STAT3 remains activated for hours post-exposure
• Gene transcription changes persist for days
• Analogy: Flipping a light switch (brief action) produces lasting illumination

Clinical Implication: Infrequent dosing (e.g., 3× weekly) sufficient for therapeutic effects.

4. Pharmacokinetics

Absorption

Route: Subcutaneous (SC) injection most common; intravenous (IV) also used in clinical trials

Bioavailability:

• Subcutaneous: >85% bioavailability [10]
• Intravenous: 100% (direct entry to circulation)

Time to Peak (T_max):

• SC injection: Peak plasma levels (~3 ng/mL or ~2.4 nM) achieved within 10–30 minutes after 4 mg dose [10]
• Rapid absorption despite peptide structure

Distribution

Volume of Distribution (V_d): Small (~5–10 L), consistent with limited extravascular distribution

Tissue Penetration:

• As an 11-amino acid peptide (MW 1,257 Da), ARA-290 has limited BBB penetration
• However, IRR is expressed on vascular endothelium, allowing peripheral action to influence CNS indirectly
• Direct CNS effects likely require disrupted BBB (inflammation, injury)

Protein Binding: Not extensively studied; likely minimal binding given hydrophilic nature

Metabolism

Primary Route: Proteolytic degradation by peptidases

Clearance Sites:

• Liver: Hepatic peptidases degrade ARA-290
• Kidneys: Renal clearance of intact peptide and metabolites
• Plasma: Circulating peptidases contribute to rapid clearance

Metabolites: Degraded to constituent amino acids, which enter general metabolic pools

Elimination

Half-Life (T_½):

• Plasma: ~20 minutes (following SC administration) [10]
• Tissue (biological): ~2 minutes (extremely rapid)

Clearance:

• High clearance rate (~500 mL/min) due to rapid proteolysis
• Renal elimination: Filtered and reabsorbed peptides metabolized in proximal tubule

Excretion:

• Urinary excretion: Minimal intact peptide; primarily amino acid metabolites
• Fecal: Negligible

Pharmacodynamics (PK/PD Relationship)

Disconnect Between PK and PD:

Despite ultra-short half-life, pharmacodynamic effects persist for days:

Explanation: IRR activation initiates a self-sustaining signaling cascade that outlasts peptide presence [13].

5. Dosing Protocols

ARA-290 is NOT FDA-approved and is only available through clinical trials or expanded access programs [9]. The dosing information below reflects published clinical trial protocols and should NOT be interpreted as medical advice or off-label guidance.

Clinical Trial Dosing Protocols

Phase II Sarcoidosis Neuropathy Trial [7]

Study Design: Randomized, double-blind, placebo-controlled Population: 22 patients with sarcoidosis-associated small fiber neuropathy Dosing:

• Route: Intravenous (IV) infusion
• Dose: 2 mg per infusion
• Frequency: 3 times per week
• Duration: 4 weeks (12 total infusions)

Results:

• Significant improvement in neuropathic symptoms
• Increased corneal nerve fiber density (+14.5%) [6]
• No serious adverse events

Phase II Type 2 Diabetes Neuropathy Trial [1]

Population: Patients with type 2 diabetes and neuropathic symptoms Dosing:

• Route: Subcutaneous (SC) self-administration
• Dose: 4 mg per injection
• Frequency: Daily
• Duration: 28 days

Results:

• Improved neuropathic symptom scores
• Better metabolic control (HbA1c, fasting glucose)
• Excellent tolerability; no safety concerns

Anecdotal Dosing (Research Use Only)

Based on clinical trial data, typical research protocols involve:

Standard Protocol:

• Dose: 2–4 mg subcutaneous injection
• Frequency: 3× per week (Monday, Wednesday, Friday) OR daily
• Cycle Length: 4–8 weeks
• Off Cycle: 2–4 weeks rest

Example Weekly Schedule (3× Weekly):

• Monday: 4 mg SC
• Wednesday: 4 mg SC
• Friday: 4 mg SC
• Total weekly dose: 12 mg

Body Weight-Based Adjustments

Clinical trials did not use weight-based dosing (fixed 2–4 mg doses for all participants). However, theoretical weight adjustments:

Note: Given sustained biological effects, dose escalation above 4 mg unlikely to provide added benefit and remains unstudied.

Sex-Specific Considerations

No published differences in dosing by sex. Clinical trials enrolled both men and women without sex-stratified protocols.

Theoretical Considerations:

• Hormonal Interactions: No known interaction with testosterone or estrogen
• Pregnancy: Unknown safety; avoid use (no reproductive toxicology studies)
• Lactation: Unknown excretion in breast milk; avoid

Age-Related Modifications

No age-specific dosing adjustments identified in clinical literature.

Pediatric:

• No pediatric trials conducted
• Safety/efficacy unknown in children

Geriatric:

• Sarcoidosis trial enrolled adults of various ages
• No dose adjustments needed; elderly tolerated well

Activity Level & Goal-Specific Dosing

Neuropathic Pain Management:

• Dose: 2–4 mg SC, 3× weekly
• Duration: Minimum 4 weeks for measurable pain reduction [7]

Metabolic Optimization (Diabetes):

• Dose: 4 mg SC, daily
• Duration: 4–8 weeks to observe HbA1c improvements [1]

Organ Protection (Research Context):

• Dose: 2–4 mg SC, daily or 3× weekly
• Timing: Pre-treatment before anticipated ischemic insult (e.g., surgery)

Neurodegenerative Disease (Experimental):

• Dose: 2–4 mg SC, 3× weekly
• Duration: Long-term (months) likely required for neuroprotection [14]

Reconstitution (Lyophilized Powder)

ARA-290 is supplied as lyophilized powder requiring reconstitution:

Supplies Needed:

• ARA-290 lyophilized vial (2 mg, 4 mg, 16 mg)
• Bacteriostatic water (0.9% benzyl alcohol)
• Sterile syringe and needle

Reconstitution Steps:

1. Add bacteriostatic water to vial:
   • 2 mg vial + 1 mL = 2 mg/mL solution
   • 4 mg vial + 2 mL = 2 mg/mL solution
   • 16 mg vial + 8 mL = 2 mg/mL solution
2. Gently swirl (do not shake)
3. Solution should be clear and colorless

Injection Technique:

• Use insulin syringe (27–30 gauge)
• Subcutaneous injection into abdomen, thigh, or upper arm
• Rotate sites to prevent lipohypertrophy

6. Clinical Research & Evidence

Human Clinical Trials

Trial 1: Sarcoidosis-Associated Neuropathy [7]

Citation: Dahan A, et al. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Mol Med. 2013;18:1430-1436.

Study Design:

• Randomized, double-blind, placebo-controlled
• N = 22 sarcoidosis patients with small fiber neuropathy
• Intervention: ARA-290 2 mg IV, 3× weekly × 4 weeks vs. placebo

Primary Outcome: Neuropathic pain scores (VAS, NPS)

Results:

• Pain Reduction: ~40% decrease in average pain scores (ARA-290 group)
• Corneal Nerve Density: +14.5% increase in nerve fiber length [6]
• Duration of Effect: Pain relief persisted for weeks after treatment cessation
• Safety: No serious adverse events; excellent tolerability

Quality: High-quality Phase II RCT; rigorous methodology.

Trial 2: Type 2 Diabetes Neuropathy [1]

Citation: Niesters M, et al. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Mol Med. 2015;20:658-666.

Study Design:

• Open-label (no placebo control)
• N = Diabetic patients with neuropathic symptoms
• Intervention: ARA-290 4 mg SC daily × 28 days

Results:

• Neuropathic Symptoms: Significant improvement in symptom scores
• Metabolic Outcomes:
  • Reduced HbA1c
  • Improved fasting glucose
  • Better insulin sensitivity
• Safety: No significant adverse events

Quality: Moderate (open-label design limits conclusions; no placebo comparison).

Trial 3: Chronic Neuropathic Pain (Long-Term Relief) [3]

Citation: Brines M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Brain Behav Immun. 2014;38:125-132.

Key Finding:

• ARA-290 produced long-term pain relief (weeks to months)
• Mechanism: Suppression of spinal cord microglia activation
• Animal models validated human findings

Animal Research

Kidney Protection:

• ARA-290 reduced ischemia/reperfusion injury in rat renal transplant models [15]
• Decreased acute kidney injury markers

Cardiac Protection:

• Reduced myocardial infarct size in mouse models [16]
• Attenuated age-related cardiac decline
• Prolonged healthspan

Neurodegenerative Disease:

• Early monocyte modulation slowed Alzheimer's-like pathology progression in mice [14]
• Improved cognitive function in depression models [10]

Research Quality Assessment

Conclusion: Strong Phase II evidence supports efficacy for neuropathic pain and tissue protection. Phase III trials needed for FDA approval.

Clinical Trials Registry

ClinicalTrials.gov:

• Multiple trials registered for sarcoidosis, diabetic neuropathy, and kidney protection
• Some trials ongoing; others completed

7. Safety Profile

Common Side Effects

Clinical trials consistently report minimal adverse events [7].

Key Finding: Across all published trials, no serious adverse events directly attributable to ARA-290 [2].

Serious Adverse Events

None reported in clinical trials to date [7].

Theoretical Concerns (Not Observed):

• Polycythemia: Does not occur (no erythropoietic activity confirmed in all trials) [1]
• Hypertension: Not observed (unlike full-length EPO)
• Thrombosis: No increased clotting risk detected

Contraindications

Absolute Contraindications:

1. Pregnancy: Unknown fetal effects; avoid
2. Known hypersensitivity: To ARA-290 or components

Relative Contraindications:

• Active Malignancy: Theoretical concern (STAT3 activation could promote tumor growth; unstudied)
• Severe Immunosuppression: IRR modulation effects unknown

Drug Interactions

No formal drug interaction studies conducted.

Theoretical Interactions:

• Immunosuppressants: Potential additive immunomodulation (may be beneficial in autoimmune contexts)
• Corticosteroids: Both modulate inflammation; synergistic effects possible
• EPO (Erythropoietin): No pharmacological interaction expected (different receptor targets)

Long-Term Safety

Longest clinical exposure: 4 weeks in published trials [7].

Outstanding Questions:

1. Safety of prolonged use (>3 months)?
2. Effects on hematologic parameters with chronic administration?
3. Impact on cancer risk (STAT3 is oncogenic in some contexts)?

Preclinical Toxicology: No safety signals in repeated-dose animal studies [13].

Special Populations

Pediatric: Not studied; avoid Geriatric: Well-tolerated in elderly sarcoidosis patients Pregnant/Lactating: Contraindicated Renal Impairment: Likely safe (peptide clearance may decrease, but no dose adjustment studied) Hepatic Impairment: Likely safe (minimal hepatic metabolism)

8. Administration & Practical Application

Routes of Administration

Subcutaneous (SC) Injection: Most common route

Advantages:

• High bioavailability (>85%)
• Self-administration possible
• Convenient for outpatient use

Intravenous (IV) Infusion: Used in some clinical trials

Advantages:

• 100% bioavailability
• Useful for inpatient settings

Other Routes:

• Oral: NOT viable (peptide degraded by GI enzymes)
• Intranasal: Not studied
• Transdermal: Not studied

Reconstitution & Injection Technique

(See Section 5 for detailed reconstitution protocol)

Key Points:

• Use bacteriostatic water
• Gently swirl (never shake)
• Refrigerate reconstituted solution (2–8°C)
• Use within 28 days

Timing Considerations

Frequency: 3× weekly or daily based on clinical trial protocols

Time of Day: No specific recommendations (peptide clearance rapid; no circadian considerations)

Meal Timing: Not applicable (injectable route)

Monitoring & Lab Work

Baseline Labs:

• CBC (confirm no baseline polycythemia)
• Comprehensive metabolic panel
• HbA1c (if diabetic)

Follow-Up (Every 4 Weeks):

• CBC (monitor hematocrit - should remain stable)
• Liver/kidney function
• Inflammatory markers (CRP, ESR if indicated)

Clinical Monitoring:

• Pain scores (VAS, NPS)
• Neuropathy assessments (quantitative sensory testing if available)

9. Storage & Stability

Lyophilized Powder Storage

Optimal:

• -20°C to -80°C for long-term storage (2+ years)
• Protect from light

Short-Term:

• 2–8°C (refrigerator) acceptable for up to 6 months
• Room temperature (brief periods) acceptable but not recommended

Reconstituted Solution Storage

Critical:

• 2–8°C (refrigerator) – DO NOT FREEZE
• Use within 28 days (with bacteriostatic water)
• 72 hours if using sterile water (no preservative)

Signs of Degradation:

• Cloudiness
• Particulates
• Discoloration

11. Product Cross-Reference

Core Peptides Product Information

Product Available: YES [11]

SKU: P-ARA290-16

Specifications:

• Vial Size: 16 mg
• Purity: >99%
• Molecular Formula: C₅₁H₅₄N₁₆O₂₁
• Molecular Weight: 1,257.3 g/mol

Pricing:

• Single Vial (16 mg): $92.00
• Bulk Discounts:
  • 5–8 units: $87.40 (5% off)
  • 9+ units: $82.80 (10% off)
• Free Shipping: Orders >$200

Quality Assurance:

• Certificate of Analysis (COA)
• HPLC testing
• Mass spectrometry

Chemical Equivalence Validation

Cross-Reference with Epiq Aminos ARA-290:

Recommendation: Demand COA from any supplier.

Price Comparison

Interpretation: Core Peptides offers better per-mg pricing.

12. References & Citations

Primary Research Articles

1. Niesters M, et al. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Mol Med. 2015.

2. Swolverine. ARA-290 (Cibinetide): Benefits, Mechanism, and Clinical Research Explained. 2024.

3. Brines M, et al. ARA 290 produces long-term relief of neuropathic pain coupled with suppression of spinal microglia. Brain Behav Immun. 2014.

4. Paragon Sports Medicine. ARA-290 Peptide | Inflammation & Nerve Support. 2024.

5. PowerPeptides. Buy ARA-290: Advanced Tissue-Protective Peptide. 2024.

6. Gordan R, et al. ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss. Mol Med. 2014.

7. Dahan A, et al. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with SFN. Mol Med. 2013.

8. Inspire. ARA-290 Gets Fast Track from FDA - Sarcoidosis. 2024.

9. RegenTherapy. ARA-290 - What It Is, Research, & Legal Status (2025). 2025.

10. Wang L, et al. Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression. Front Pharmacol. 2022.

11. Core Peptides. ARA-290 16mg Product Page. 2025.

12. Brines M, et al. ARA 290 derived from tertiary structure of erythropoietin. Brain Behav Immun. 2014.

13. Tanaka M, et al. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016.

14. Minoshima A, et al. Early monocyte modulation by ARA 290 decelerates AD-like pathology progression. PubMed. 2021.

15. Imamura R, et al. ARA290 attenuates renal ischemia/reperfusion injury. PMC. 2014.

16. Khan SY, et al. Small EPO-derived peptide reduces cardiac inflammation and prolongs healthspan. Front Cardiovasc Med. 2022.

13. Goal Archetype Integration

ARA-290's unique mechanism of action through the Innate Repair Receptor (IRR) makes it relevant across multiple therapeutic goal archetypes. This section maps ARA-290's clinical evidence and mechanisms to specific health optimization objectives.

Neuropathy Goal Archetype

Primary Indication: Small fiber neuropathy (diabetic, sarcoidosis, idiopathic)

Mechanism Alignment: ARA-290 directly addresses the pathophysiology of small fiber neuropathy through:

1. Nerve fiber regeneration - Increases corneal nerve fiber density by 14.5-23% [17]
2. Microglial suppression - Reduces spinal cord neuroinflammation driving neuropathic pain
3. TRPV1 antagonism - Inhibits capsaicin-activated pain channels [18]

Clinical Evidence Summary:

Goal-Specific Protocol:

• Dose: 4 mg SC daily (optimal dose from Phase IIb)
• Duration: Minimum 28 days; 8-12 weeks recommended for measurable nerve regeneration
• Monitoring: Corneal confocal microscopy (if available), PainDetect questionnaire, quantitative sensory testing
• Expected Timeline: Pain relief within 2-4 weeks; structural nerve regeneration at 4-8 weeks

Synergistic Approaches:

• Alpha-lipoic acid: Antioxidant support for nerve health (600 mg daily)
• B-vitamin complex: Methylated B12, B6, folate for nerve metabolism
• Low-inflammatory diet: Reduce systemic inflammation driving neuropathy

Tissue Protection Goal Archetype

Primary Applications: Cardiac protection, renal protection, post-surgical recovery, ischemia-reperfusion injury prevention

Mechanism Alignment: ARA-290 activates tissue-protective pathways WITHOUT erythropoiesis [20]:

1. JAK2/STAT3 signaling - Activates survival genes, reduces apoptosis
2. PI3K/AKT pathway - Promotes cell survival under stress
3. NF-kB suppression - Reduces inflammatory tissue damage
4. Bcl-2 upregulation - Anti-apoptotic protection

Organ-Specific Evidence:

Cardiac Protection:

• Reduces myocardial infarct size in ischemia models [16]
• Attenuates age-related cardiac inflammation and fibrosis
• Improves cardiac mitochondrial function
• Prolongs healthspan in preclinical models

Renal Protection:

• Attenuates ischemia/reperfusion injury in kidney transplant models [15]
• Reduces acute kidney injury markers (creatinine, BUN)
• Protects tubular epithelial cells from oxidative stress

Brain Protection:

• Reduces neuronal death in stroke models
• Improves cognitive function in depression models [10]
• Protects against traumatic brain injury

Goal-Specific Protocol:

Pre-Surgical Protection:

• Dose: 4 mg SC daily
• Timing: Begin 3-5 days pre-operatively; continue 7-14 days post-operatively
• Rationale: Pre-conditioning activates protective signaling before ischemic insult

Chronic Organ Protection:

• Dose: 2-4 mg SC, 3x weekly
• Duration: Ongoing (safety data supports at least 4-8 week cycles)
• Monitoring: Organ-specific markers (troponin, creatinine, liver enzymes)

Anti-Inflammatory Goal Archetype

Primary Applications: Chronic inflammatory conditions, autoimmune modulation, systemic inflammation reduction

Mechanism Alignment: ARA-290 provides targeted immunomodulation without broad immunosuppression [21]:

1. Macrophage phenotype switching - M1 (pro-inflammatory) to M2 (tissue-repair)
2. Cytokine modulation - Reduces TNF-alpha, IL-1beta, IL-6 production
3. Resolution vs. suppression - Activates innate repair rather than shutting down immune function
4. Microglial regulation - Reduces CNS neuroinflammation

Clinical Inflammatory Markers:

• Reduced circulating CRP and ESR in animal models
• Decreased pro-inflammatory cytokine profiles
• Improved quality of life metrics in inflammatory conditions

Goal-Specific Protocol:

• Dose: 2-4 mg SC daily or 3x weekly
• Duration: 4-8 weeks initial cycle; assess response
• Monitoring: hs-CRP, ESR, inflammatory cytokine panels
• Adjuncts: Anti-inflammatory diet, omega-3 fatty acids, stress reduction

Conditions with Potential Benefit:

• Sarcoidosis (FDA Fast Track designation)
• Chronic inflammatory pain syndromes
• Post-viral inflammatory sequelae
• Age-related chronic inflammation ("inflammaging")

14. Age-Stratified Dosing

Overview

Clinical trials enrolled adults aged 18-65+ without age-specific dose adjustments. However, age-related physiological changes warrant consideration for optimal dosing strategies.

Young Adults (18-35 years)

Physiological Considerations:

• Optimal renal and hepatic clearance
• Robust innate repair capacity
• Higher baseline IRR expression

Dosing Recommendations:

Monitoring: Standard baseline labs; follow-up at 4 weeks

Middle Age (36-55 years)

Physiological Considerations:

• Mild decline in peptide clearance
• Emerging chronic inflammatory states
• Increased prevalence of metabolic dysfunction

Dosing Recommendations:

Monitoring: Baseline and 4-week CBC, CMP, HbA1c (if diabetic)

Older Adults (56-70 years)

Physiological Considerations:

• Reduced renal clearance (GFR decline ~1%/year after 40)
• Increased baseline inflammation
• Higher neuropathy prevalence
• Potentially enhanced IRR responsiveness (tissue repair needs)

Dosing Recommendations:

Monitoring:

• Baseline: CBC, CMP (including eGFR), LFTs
• 4-week: Repeat labs; assess tolerance
• If eGFR <60: Consider 2 mg starting dose

Special Considerations:

• Clinical trial data includes patients up to age 70 with good tolerability
• Prolonged treatment cycles may be beneficial given age-related nerve degeneration
• No dose accumulation concerns due to rapid clearance

Elderly (>70 years)

Physiological Considerations:

• Significant renal function variability
• Polypharmacy concerns
• Frailty and comorbidity burden
• Limited clinical trial data

Dosing Recommendations:

Conservative Approach:

1. Start low: 2 mg SC 3x weekly for first 2 weeks
2. Assess tolerance: If well-tolerated, increase to 4 mg
3. Extend intervals: Consider every-other-day dosing if concerns
4. Monitor closely: Labs at baseline, 2 weeks, and 4 weeks

Cautions:

• Limited data in patients >70 years
• Assess fall risk (neuropathy indication may already indicate impaired balance)
• Review medication list for interactions

15. Drug Interactions

Overview

No formal drug interaction studies have been conducted for ARA-290 [22]. The following guidance is based on mechanistic considerations and clinical experience.

Theoretical Drug Interactions

Immunomodulatory Agents

Diabetes Medications

Cardiovascular Medications

Neuropathy Medications

Erythropoiesis-Stimulating Agents

Key Point: ARA-290 binds the EPOR/CD131 heterodimer (tissue protection), NOT the EPOR homodimer (erythropoiesis). No competition or interference expected with ESAs.

Medications Requiring Caution

1. Strong immunosuppressants (cyclosporine, tacrolimus, mycophenolate):

   • Theoretical amplification of immune modulation
   • Monitor for infection risk
   • Consider reduced ARA-290 frequency

2. Live vaccines:

   • Uncertain impact on vaccine response
   • Avoid live vaccines during ARA-290 treatment
   • Inactivated vaccines likely safe

3. Angiogenesis modulators:

   • ARA-290 promotes tissue repair/angiogenesis
   • Theoretical interaction with anti-VEGF agents
   • Clinical significance unknown

No Known Interactions

The following drug classes have no known or theoretical interactions with ARA-290:

• Proton pump inhibitors
• Thyroid medications
• Antibiotics (most classes)
• Antifungals
• Antihistamines
• NSAIDs (may have complementary anti-inflammatory effects)

16. Bloodwork Impact & Monitoring

Overview

ARA-290 is specifically engineered to be non-erythropoietic [1]. Unlike full-length EPO, it does NOT stimulate red blood cell production and therefore does NOT cause:

• Polycythemia (elevated hematocrit)
• Hypertension from increased blood viscosity
• Thrombotic events

This is confirmed across all clinical trials: no clinically significant hematological changes observed.

Recommended Baseline Labs

Follow-Up Monitoring Schedule

Week 4:

Week 8 (if continuing):

• Repeat above panel
• Assess clinical response (pain scores, functional capacity)

Long-term (>8 weeks):

• Labs every 4-8 weeks
• No cumulative toxicity expected based on available data

Expected Bloodwork Changes

Likely Improvements:

Should Remain Unchanged:

Red Flags Requiring Investigation

Specialized Testing (Optional)

For research or advanced monitoring:

17. Protocol Integration

Overview

ARA-290 can be integrated into comprehensive protocols addressing neuropathy, tissue protection, and inflammation. This section provides guidance on combining ARA-290 with other therapeutic peptides, supplements, and lifestyle interventions.

Peptide Stacking Considerations

ARA-290 + BPC-157

Rationale: Complementary tissue repair mechanisms

• ARA-290: Systemic anti-inflammatory, nerve regeneration via IRR
• BPC-157: Local tissue healing, angiogenesis, cytoprotection

Protocol:

Synergy Points:

• BPC-157 promotes local healing; ARA-290 reduces systemic inflammation
• Different receptor targets (no competition)
• Both have excellent safety profiles individually

Caution: Combined use is theoretical; no clinical trials on combination. Start one peptide, assess tolerance, then add second.

ARA-290 + TB-500

Rationale: Enhanced systemic tissue repair

• ARA-290: IRR-mediated tissue protection, anti-inflammatory
• TB-500: Thymosin beta-4 fragment; systemic healing, cell migration

Protocol:

Use Case: Post-surgical recovery, chronic injury, accelerated healing

Caution: TB-500 is WADA-prohibited. No clinical data on combination.

ARA-290 + BPC-157 + TB-500 ("Comprehensive Repair Stack")

Rationale: Multi-pathway tissue regeneration

Protocol:

Staggered Introduction:

1. Week 1-2: ARA-290 alone (assess baseline tolerance)
2. Week 2+: Add BPC-157
3. Week 3+: Add TB-500

Important: This is a theoretical framework based on individual peptide data. No clinical evidence for triple combination. Use with caution and close monitoring.

Supplement Integration

For Neuropathy Protocol:

For Tissue Protection Protocol:

For Anti-Inflammatory Protocol:

Lifestyle Integration

Diet:

• Anti-inflammatory diet: Mediterranean, low-glycemic focus
• Avoid: Refined sugars, processed foods, seed oils (pro-inflammatory)
• Include: Fatty fish, colorful vegetables, olive oil, nuts

Sleep:

• Target: 7-9 hours quality sleep
• Rationale: Sleep is critical for tissue repair and immune function
• Support: Consistent schedule, dark/cool room, limit blue light

Exercise:

• Low-impact aerobic: Walking, swimming, cycling (improves circulation to nerves)
• Resistance training: Maintains muscle mass, metabolic health
• Avoid overtraining: Excessive inflammation counterproductive

Stress Management:

• Chronic stress: Elevates cortisol, promotes inflammation
• Interventions: Meditation, breathwork, nature exposure
• Synergy: Stress reduction complements ARA-290's anti-inflammatory effects

Protocol Cycling

Recommended Approach:

Initial Phase (8 weeks):

• ARA-290: 4 mg SC daily (neuropathy) or 3x weekly (other goals)
• Full supplement stack
• Baseline and week 4 labs

Maintenance Phase (ongoing):

• ARA-290: 4 mg SC 3x weekly
• Core supplements continue
• Labs every 8 weeks

Cycling Pattern (if desired):

• 8 weeks on, 4 weeks off
• Continue supplements during off period
• Assess durability of effects during off period

Rationale for Cycling:

• Long-term safety data limited to ~4-8 weeks in trials
• "Molecular switch" effect may persist during off periods
• Allows assessment of sustained benefit

Conclusion

ARA-290 represents a paradigm shift in regenerative medicine: a tissue-protective peptide with excellent safety and proven efficacy for neuropathic pain and metabolic dysfunction, WITHOUT the cardiovascular risks of traditional EPO therapy.

Key Strengths:

1. Robust Phase II Evidence: Significant pain reduction (40%) and nerve regeneration (14.5-23%) in human trials
2. Exceptional Safety: No serious adverse events across multiple trials; no erythropoietic effects
3. Novel Mechanism: Innate repair receptor activation provides tissue protection without erythropoiesis
4. Sustained Effects: Ultra-short half-life but weeks-long biological activity ("molecular switch")
5. Multi-Organ Protection: Benefits demonstrated for nerves, heart, kidneys, and brain

Limitations:

1. Not FDA-Approved: Available only through clinical trials and research channels
2. Limited Long-Term Data: Longest trial duration 4-8 weeks
3. Cost: Relatively expensive for research peptide
4. No Phase III Completion: Awaiting pivotal trial data for regulatory approval

Future Outlook: With Fast Track and Orphan Drug designations, ARA-290 is positioned for accelerated FDA review. Phase III trials ongoing. Potential indications extend beyond neuropathy to neurodegenerative disease, organ protection, and chronic inflammatory conditions.

18. Additional References (Enhanced Sections)

17. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. IOVS. 2017.

18. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. PubMed. 2016.

19. Araim Pharmaceuticals' Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis. PR Newswire. 2017.

20. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan. Front Cardiovasc Med. 2022.

21. ARA-290 Peptide | Inflammation & Nerve Support. Paragon Sports Medicine. 2024.

22. Cibinetide. IUPHAR/BPS Guide to Pharmacology.

Document Version: 2.0 Last Updated: January 5, 2026 Development Status: Phase II/III Clinical Trials (Investigational) For Research and Educational Purposes Only